Molecular mechanism of activation and nuclear translocation of the mineralocorticoid receptor upon binding of pregnanesteroids

Molecular and Cellular Endocrinology

Volumn 217, Issue 1-2, 2004, Pages 167-179

  Galigniana, M D ^a,b   Pilipuk, G Piwien ^a   Kanelakis, K C ^b   Burton, G ^c   Lantos, C P ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

11,19 Oxidoprogesterone; Aldosterone; Dynein; Immunophilins; Natriuresis; Trafficking

Indexed keywords

11,19 OXIDOPROGESTERONE; 11BETA HYDROXYPROGESTERONE; 5ALPHA PREGNANE 3,20 DIONE; 5BETA DIHYDROPROGESTERONE; 6,19 OXIDOPROGESTERONE; ALDOSTERONE; DEOXYCORTICOSTERONE; DYNEIN ADENOSINE TRIPHOSPHATASE; LIGAND; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; PREGN 4 ENE 3,11,20 TRIONE; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

BINDING AFFINITY; CELL NUCLEUS; COMPLEX FORMATION; CONFERENCE PAPER; CONFORMATION; CYTOPLASM; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; IN VIVO STUDY; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION; HUMANS; PREGNENEDIONES; PROTEIN BINDING; PROTEIN CONFORMATION; RATS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 2342586714     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.041     Document Type: Conference Paper

References (57)

1. Agarwal M.K., Mirashi M. General overview of mineralocorticoid action. Pharmacol. Ther. 84:2000;273-326
2. Aridor A., Hannan L.A. Traffick jams II: an update of diseases of intracellular transport. Traffic. 3:2002;781-790
3. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 237:1987;268-275
4. Bastl C.P., Hayslett J.P. The cellular action of aldosterone in target epithelia. Kidney Int. 42:1992;250-264
5. Black B.E., Holaska J.M., Rastinejad F., Paschal B.M. DNA binding domains in diverse nuclear receptors function as nuclear export signals. Curr. Biol. 11:2001;1749-1758
6. Brachet-Cota, A.L., Burton, G., 1990. An improved preparation of 11,19-oxidopregn-4-ene-3, 20-dione and 6,19-oxidopregn-4-ene-3,11,20-tri-one. Z. Naturforsch. 45, 711; 715.
7. Burton G., Galigniana M.D., deLavallaz S., Brachet-Cota A.L., Sproviero E.M., Ghini A.A., Lantos C.P., Damasco M.C. Sodiun-retaining activity of some natural and synthetic 21-deoxysteroids. Mol. Pharmacol. 47:1995;535-543
8. DeFranco D. Navigating steroid hormone receptors through the nuclear compartment. Mol. Endocrinol. 16:2002;1449-1455
9. Dluhy R.G. Glucocorticoid-remediable aldosteronism. Endocrinilogist. 11:2001;2263-2268
10. Edwards C.R.W., Stewart P.M., Burt D., Bret L., McIntyre M.A., Sutanto W.S., de Kloet E.R., Monder C.L. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 2:1988;986-989
11. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895
12. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:1998;3317-3325
13. Fejes-Tóth G., Pearce D., Náray-Fejes-Tóth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2973-2978
14. Funder J.W., Pearce P., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 242:1988;583-585
15. Funder J.W., Miles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 137:1996;5264-5268
16. Galigniana M.D., Vicent G.P., Lantos C.P., Burton G. Ligand properties of 11, 19-xidoprogesterone: a preliminary report. An. Assoc. Quím. Argent. 81:1993;333-340
17. +-retaining steroid binding to an alternative site in rat kidney type I receptor. Eur. J. Endocrinol. 130:1994;260
18. Galigniana M.D., Vicent G.P., Lantos C.P., Burton G. Features of the shuttle pair 11β-hydroxyprogesterone/11-ketoprogesterone. Steroids. 62:1997;358-364
19. Galigniana M.D. Native rat kidney mineralocorticoid receptor is a phosphoprotein whose transformation to a DNA-binding form is induced by phosphatases. Biochem. J. 333:1998;555-563
20. Galigniana M.D. Functional regulation of corticosteroid receptors by phosphorylation and redox potential. Curr. Topics Steroid Res. 3:2000;1-22
21. Galigniana M.D., Vicent G.P., Piwien-Pilipuk G., Burton G., Lantos C.P. Mechanism of action of the potent sodium-retaining steroid 11, 19-oxidoprogesterone. Mol. Pharmacol. 58:2000;58-70
22. Galigniana M.D., Radanyi C., Renoir J.M., Housley P.R., Pratt W.B. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem. 276:2001;14884-14889
23. Galigniana M.D., Harrell J.M., Murphy P.J.M., Chinkers M., Radanyi C., Renoir J.M., Zhang M., Pratt W.B. Binding of hsp90-associated immunophilins to cytoplasmic dynein: direct binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein interaction domain. Biochemistry. 41:2002;13602-13610
24. Gómez-Sánchez E.P., Venkataraman M.T., Thwaites D., Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258:1990;E649-E653
25. Grassi G., Fagart J., Calas B., Adenot M., Rafestin-Oblin M.E., Auzou G. Structure-activity relationships of steroids with mineralocorticoid activity. Eur. J. Med. Chem. 32:1997;869-879
26. Heap R.B., Holzbauer M., Newport H.M. Adrenal secretion rates of C19 and C21 steroids after hypophysectomy in the pig and the dog. J. Endocrinol. 36:1966;159-176
27. Hutter H., Vogel B.E., Plenefisch J.D., Norris C.R., Proenca R.B., Spieth J., Guo C., Mastwal S., Zhu X., Scheel J., Hedgecock E.M. Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes. Science. 287:2000;989-994
28. Iida T., Furutani M., Nishida F., Maruyama T. FKBP-type peptidyl-proplyl cis-trans isomerase from a sulfur-dependent hyperthermophilic archaeon, Thermococcus sp. KS-1. Gene. 222:1998;249-255
29. Kitagawa H., Yanagisawa J., Fuse H., Ogawa S., Yogiashi Y., Okuno A., Nagasawa H., Nakajima T., Matsumoto T., Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acethyltransferase complex. Mol. Cell. Biol. 22:2002;3698-3706
30. Kraulis I., Traikov H., Li M., Birmingham M.K. The effects of corticosterone, 18-OH-DOC, DOC and 11-hydroxyprogesterone on the adrenal pituitary axis of the stressed rat. J. Steroid Biochem. 4:1973;129-137
31. Lantos, C.P., Burton, G., Roldán, A., Damasco, M.C., Aragonés, A., 1981. Structure-activity relationship in certain glucocorticoids and mineralocorticoids. In: Soto, R.J., de Nicola A., Blaquier, J. (Eds.), Physiopathology of Endocrine Diseases and Mechanisms of Hormone Action. Alan R. Liss, New York, pp. 477-494.
32. Laudet V. Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J. Mol. Endocrinol. 19:1997;207-226
33. Lim-Tio S.S., Fuller P.J. Intacellular signaling pathways confer specificity of transactivation by mineralocorticoid and glucocorticoid receptors. Endocrinology. 139:1998;1653-1661
34. Liu W., Wang J., Sauter N.K., Pearce D. Steroid receptor heterodimerization demonstrated in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12480-12484
35. Lombès M., Binart N., Delahaye F., Baulieu E.E., Rafestin-Oblin M.E. Differential intracellular localization of human mineralocorticoid receptor on binding of agonists and antagonists. Biochem. J. 302:1994;191-197
36. Marks A.R. Cellular functions of immunophilins. Physiol. Rev. 76:1996;631-649
37. McDonnell D.P., Shabaz M.M., Vegeto E., Goldman M.E. Progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J. Steroid Biochem. Mol. Biol. 48:1994;425-432
38. Morimoto R.I. Dynamic remodeling of transcription complexes by molecular chaperones. Cell. 110:2002;281-284
39. Nishi M., Ogawa H., Ito T., Matsuda K.-I., Kawata M. Dynamic changes in subcellular localization on mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants. Mol. Endocrinol. 15:2001;1077-1092
40. Pearce D., Náray-Fejes-Tóth A., Fejes-Tóth G. Determinants of subnuclear organization of mineralocorticoid receptor characterized through analysis of wild type and mutant receptors. J. Biol. Chem. 277:2002;1451-1456
41. Piwien-Pilipuk G., Galigniana M.D. Tautomycin inhibits phosphatase-dependent transformation of the rat kidney mineralocorticoid receptor. Mol. Cell. Endocrinol. 144:1998;119-130
42. Piwien-Pilipuk G., Kanelakis K.C., Ghini A.A., Lantos C.P., Litwack G., Burton G., Galigniana M.D. Modification of an essential amino group in the mineralocorticoid receptor evidences a differential conformational change of the receptor protein upon binding of antagonists, natural agonists and the synthetic agonist 11, 19-oxidoprogesterone. Biochem. Biophys. Acta. 1589:2000;31-48
43. Piwien-Pilipuk G., Kanelakis K.C., Galigniana M.D. Correlation between pregnanesteroid conformation, receptor affinity, and anti-natriuretic effect. Eur. J. Pharmacol. 454:2002a;131-143
44. Piwien-Pilipuk G., Galigniana M.D. Oxidative stress by L-buthionine-(S, R)-sulfoximine, a selective inhibitor of glutathione metabolism, abrogates mouse kidney mineralocorticoid receptor function. Biochem. Biophys. Acta. 1495:2002b;263-280
45. Piwien-Pilipuk G., Ayala A., Machado A., Galigniana M.D. Impairment of mineralocorticoid receptor (MR)-dependent biological response by oxidative stress and aging. Correlation with post-translational modification of MR and decreased ADP-ribosylatable level of elongation factor 2 in kidney cells. J. Biol. Chem. 277:2002c;11896-11903
46. Pratt W.B. The role of heat shock proteins in regulationg the function, folding, and trafficking of the glucocorticoid receptor. J. Biol. Chem. 268:1993;21455-21458
47. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrinol. Rev. 18:1997;306-360
48. Quinkler M., Meyer B., Bumke-Vogt C., Grossmann C., Gruber U., Oelkers W., Diederich S., Bahr V. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur. J. Endocrinol. 146:2002;789-800
49. Robertson N.M., Schulman G., Karnik S., Alnemri E., Litwack G. Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using anti-MR antibody and confocal scanning microscopy. Mol. Endocrinol. 7:1993;1226-1239
50. Sato A., Sheppard K.E., Fullerton M.J., Sviridov D.D., Funder J.W. Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells. Endocrinology. 136:1995;3707-3713
51. Silverstein A.M., Galigniana M.D., Kanelakis K.C., Radanyi C., Renoir J.M., Pratt W.B. Different regions of the immunophilin FKBP52 determine its association with the glucocorticoid receptor, hsp90, and cytoplasmic dynein. J. Biol. Chem. 274:1999;36980-36986
52. Souness G., Latif S., Laurenzo J., Morris D.J. 11α- and 11β-Hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rats. Endocrinology. 136:1995;1809-1812
53. Trapp T., Rupprecht R., Castren M., Reul M., Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron. 13:1994;1457-1462
54. Van Steensel B., Van Binnendjik E.P., Honrsby C.D., Van der Voort H.T.M., Krozowski Z.S., de Kloet E.R., Van Driel R. Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. J. Cell Sci. 109:1996;787-792
55. Vicent G.P., Pecci A., Ghini A.A., Piwien-Pilipuk G., Galigniana M.D. Differences in nuclear retention characteristics of agonist-activated glucocorticoid receptor may determine specific biological responses. Exp. Cell Res. 276:2002;142-154
56. Young D.B. Quantitative analysis of aldosterone's role in potassium regulation. Am. J. Physiol. 255:1988;F811-F822
57. Young M., Fullerton M., Dilley R., Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93:1994;2578-2583